Gastroenterology Research of San Antonio — San Antonio, Texas

Gastroenterology Research of San Antonio is a clinical research site located in San Antonio, Texas, United States 78229.

Crixeo Clinical Trials Trust Score: 25/100 (FAILING). This profile has not yet been claimed by the site owner.

Gastroenterology Research of San Antonio has participated in 39 clinical trials with 13 currently active.

Therapeutic areas: Ulcerative Colitis, Diabetic Gastroparesis, Non-Erosive Gastro-Esophageal Reflux Disease.

Sponsors: Takeda, CinDome Pharma, Inc., Phathom Pharmaceuticals, Inc..

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in San Antonio

Browse all research sites in Texas · View every site in San Antonio

Sponsor Feasibility Report

Trust Score: 25/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Gastroenterology Research of San Antonio?

Gastroenterology Research of San Antonio has a Crixeo Trust Score of 25/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Gastroenterology Research of San Antonio conducted?

Gastroenterology Research of San Antonio has 39 clinical trials on record, with 13 currently active. Their work covers Ulcerative Colitis, Diabetic Gastroparesis, Non-Erosive Gastro-Esophageal Reflux Disease.

Is Gastroenterology Research of San Antonio accredited by Crixeo Clinical Trials?

Gastroenterology Research of San Antonio has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Gastroenterology Research of San Antonio?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.